NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacyTakahiro Miyazaki, Jonathan Zalevsky, Janet Cetz et al.|Journal for ImmunoTherapy of Cancer|2021Cited by 55
Bempegaldesleukin (<scp>BEMPEG</scp>; <scp>NKTR</scp>‐214) efficacy as a single agent and in combination with checkpoint‐inhibitor therapy in mouse models of osteosarcomaMarlene Hennessy, Nancy Gordon, Mariella Cabrera et al.|International Journal of Cancer|2020Cited by 20
Abstract 3755: Comprehensive antitumor immune activation by a novel TLR7/8 targeting agent NKTR-262 combined with CD122-biased immunostimulatory cytokine NKTR-214Saul Kivimäe, Jonathan Zalevsky, Marlene Hennessy et al.|Cancer Research|2018Cited by 19
REVEAL: A phase I/II, open-label, multicenter, dose escalation and dose expansion study of NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] with or without nivolumab (nivo) in patients (pts) with locally advanced or metastatic solid tumor malignanciesAdi Diab, Sandra P. D’Angelo, Mario Q. Marcondes et al.|Annals of Oncology|2018Cited by 7
NKTR-255, a Polymer-Conjugated IL-15 Enhances Antibody-Dependent Cellular Cytotoxicity Mediated By NK Cells in a B Cell Lymphoma ModelTakahiro Miyazaki, Jonathan Zalevsky, Saul Kivimäe et al.|Blood|2019Cited by 5